^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Glioma |
| Drug: | Temodex (temozolomide gel) (DNA synthesis inhibitor, Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion
Excerpt:
IDHmt was predictive of benefit from adjTMZ (IDHmt HR: 0.41, 95% CI 0.27, 0.64; IDHwt: HR 1.05, 95% CI 0.73, 1.52; interaction test p = 0.001). In IDHmt patients that received adjTMZ, the HR for OS after concTMZ was 0.71 (95% CI 0.35, 1.42, p=0.32)...in IDHmt tumors a trend towards benefit of concTMZ is present. AdjTMZ increased OS in IDHmt but not in IDHwt tumors.
DOI:
10.1200/JCO.2019.37
Trial ID:
Source:
Title:
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Excerpt:
IDH mutation and 1p-19q codeletion were associated with prolonged overall survival in univariate (p=0.002 and p=0.0001) and multivariate analysis (p=0.003 and p=0.004). 1p-19q codeletion, MGMT promoter methylation, and IDH mutation (p=0.01) were correlated with a higher rate of response to temozolomide.
DOI:
10.1212/WNL.0b013e3181f96282
